Navigation Links
Drug Safety Firm BioSoteria Announces Exponential Growth in 2009
Date:1/28/2010

BioSoteria announced today that revenues grew 67% in 2009 compared to 2008. The strong growth came from an increase in new client contracts, expanded drug safety services to existing clients, and the launch of eLadder™ Safety, a comprehensive pharmacovigilance eLearning curriculum.

(PRWEB) January 28, 2010 -- BioSoteria, Inc., a privately held drug safety services and training company, announced today that revenues grew 67% in 2009 compared to 2008. The strong growth came from an increase in new client contracts, expanded services to existing clients, and the launch of eLadder™ Safety, a first-in-class comprehensive pharmacovigilance eLearning curriculum.

In 2009, BioSoteria provided consulting and safety operational services to more than 40 biotechnology and pharmaceutical companies across the US and Canada. The company’s substantial increase in revenues in 2009 was realized as clients increasingly engaged BioSoteria for strategic consulting and services in areas such as risk evaluation and mitigation strategies (REMS) and safety signal detection and analysis. Professional staff grew by 19% to support the demand for BioSoteria’s drug safety services and training offerings.

Also contributing to the increase in corporate growth was the launch of BioSoteria’s eLadder™ Safety pharmacovigilance training curriculum. The first three eLearning courses of the curriculum released in 2009 were enthusiastically received by drug safety professionals, those aspiring to enter the field of drug safety, and by biopharmaceutical companies and contract research organizations (CROs) that wish to train their safety personnel. The BioSoteria website was upgraded to include an eCommerce engine that allows individuals and small companies to purchase access to eLadder™ Safety courses online. Enterprise license options for corporate/institutional buyers were also introduced.

“I am very pleased with our leadership position in drug safety and continued growth of our company in 2009,” said Sally Van Doren, PharmD, President, CEO and Founder of BioSoteria. “In just three years, BioSoteria has grown from a small consulting firm providing services to primarily West Coast clients to a well recognized, full-service pharmacovigilance service and training provider across North America with a dedicated team of nearly 50 drug safety professionals, educational and training staff and operational support. We look forward to continuing our high quality services and extending our offerings in 2010 through business expansion and strategic partnerships.”

Highlights of 2009
-- Safety consulting and operational services were provided to more than 40 biotechnology, pharmaceutical, and over-the counter (OTC) companies, including:

 
  • Case intake, data entry, narratives, coding, reporting to regulatory authorities, periodic safety reporting, company core data sheet (CCDS) development and maintenance, and labeling updates
  • Patient narratives, integrated summary of safety (ISS) and other medical writing support for NDAs, BLAs, and MAAs
  • Hosted safety database solutions
  • Risk management/REMS planning, document writing, and implementation
  • Safety signal detection and analysis using client, FDA AERS, and other health databases
  • Pharmacovigilance department audits and US/EU inspection readiness
  • Product litigation consulting and support
  • Support to clients with complete response letters and programs placed on clinical hold

-- eLadder™ Safety, the first comprehensive drug safety training curriculum delivered in a true multimedia eLearning environment, was launched, with three core competency courses for drug safety professionals:
 

-- The BioSoteria leadership team expanded with the addition of James Buchanan, PharmD, as Senior Vice President of Pharmacovigilance and Risk Management. Dr. Buchanan has more than 20 years of industry drug safety, clinical development, and medical information services experience, and he has served as Chief Safety Officer at two past companies prior to joining BioSoteria.

-- BioSoteria moved its corporate headquarters to Emeryville CA, central to many biotechnology and pharmaceutical companies in the San Francisco Bay Area, to accommodate the current and future growth in its staff and drug safety services.

-- DSI: Drug Safety Intelligence, BioSoteria’s weekly drug safety e-newsletter, grew to nearly 1100 subscribers.

-- BioSoteria’s 3rd Annual Pacific Drug Safety Summit ( PDSS09) had the highest attendance, sponsorship and satisfaction rankings to date, making it one of the most well attended pharmacovigilance conferences in the US of the year.

-- Several of the BioSoteria senior management team accepted faculty and instructor appointments and lectured throughout the year at Universities, Schools of Pharmacy, as well as industry conferences, on drug development and drug safety.

About BioSoteria, Inc.
BioSoteria provides innovative drug safety services and educational programs to the biopharmaceutical industry. The company offers a wide range of pharmacovigilance services throughout the product lifecycle, including premarketing clinical safety surveillance, postmarketing pharmacovigilance, and risk management programs. For more information about BioSoteria, please visit the company’s website at www.biosoteria.com, email contact@biosoteria.com, or call 1-866-660-5553.

###

Read the full story at http://www.prweb.com/releases/drugsafety/pharmacovigilance/prweb3533344.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Related biology technology :

1. RFID tags to boost transit worker safety
2. FDA researchers identify new MRI safety risk for patients with pacemakers
3. Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced
4. S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders
5. Sangamo BioSciences Provides Update on Phase 1 Safety Trial of SB-728-T for HIV/AIDS
6. BioSoteria CEO to Present at Drug Safety Conference
7. Sanofi Pasteur Presents Safety Data on Menactra(R) Vaccine Given to Infants at Infectious Disease Society Meeting
8. Safety in Drinking Water? Monitoring for Radioactive Contaminants Only Required Every Three, Six, or Nine Years per Federal Law
9. BioSoteria Drug Safety Newsletter Reaches Milestone
10. 17th International Process Development Conference to Feature Presentations on Safety, Process Development, Crystallization, PAT, Scale-Up and Production
11. Global Pharmaceutical Company Awards Comprehensive Cardiac Safety Study to iCardiac
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... Massachusetts (PRWEB) , ... May 23, 2017 , ... ... making a splash at this year’s Bio-IT World Conference and Expo in ... Smart Data Lake® 4.0 solution. The Anzo Smart Data Lake is also a ...
(Date:5/22/2017)... ... 22, 2017 , ... Cancer diagnostics and pathology workflow solution ... the Association for Pathology Informatics Annual Summit at the Wyndham Grand ... Cancer Diagnostic Cockpit and Consultation Portal, Inspirata will present research it led to ...
(Date:5/19/2017)... ... 19, 2017 , ... The University City Science Center is ... for commercialization, and who are affiliated with the 21 partner academic and research ... now in its tenth round, is the first multi-institutional proof-of-concept program for the ...
(Date:5/18/2017)... ... May 17, 2017 , ... NDA Partners Chairman ... former CEO of Eurofins Advantar Laboratories and President of Pharmaceutical Development Business Unit of ... position at Eurofins and Cardinal Health, he was former Chief Operating Officer at Anaborex, ...
Breaking Biology Technology:
(Date:4/6/2017)... Forecasts by Product Type (EAC), ... End-Use (Transportation & Logistics, Government & Public Sector, Utilities ... Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), ... you looking for a definitive report on the $27.9bn ... ...
(Date:4/5/2017)... 2017 KEY FINDINGS The global ... a CAGR of 25.76% during the forecast period of ... factor for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is ... geography. The stem cell market of the product is ...
(Date:3/30/2017)...  On April 6-7, 2017, Sequencing.com will host the ... hackathon at Microsoft,s headquarters in Redmond, Washington ... developing health and wellness apps that provide a unique, ... is the first hackathon for personal genomics and ... in the genomics, tech and health industries are sending ...
Breaking Biology News(10 mins):